Amide Technologies, a biotech that synthesizes challenging peptides, announced today that it has begun commercializing its novel peptide manufacturing platform. The company also announced it has raised $16.5 million in total funding to date, which includes a $7.5 million Series A Extension investment closed in July 2023 led by Engine Ventures with participation from Forcefield Venture Fund. Previous rounds included a $3.55M Series A, also led by Engine Ventures, and a $5.45M Seed Round led by Biological Engineering Ventures.

Amide Technologies is a biotech startup offering on-demand complex peptide manufacturing at unprecedented speed. Through its novel manufacturing platform developed at MIT, Amide is bridging the gap between traditional solid phase peptide synthesis and biological expression, empowering scientists on the cutting edge of peptide drug design.